Fibrobiologics Inc. (FBLG)
NASDAQ (CM) NASDAQ (CM) Primary Summary
FibroBiologics advances diabetic ulcer trial with new drug shipment to Australia
FibroBiologics (NASDAQ:FBLG), a clinical-stage biotechnology company, has released and shipped the third batch of its experimental drug product, CYWC628, to Australia to support an ongoing clinical trial for diabetic foot ulcers (DFUs). The compant describes the investigational treatment as a topically applied allogeneic cell therapy that uses donor fibroblasts, a type of specialized connective tissue cell, to accelerate wound healing.
Fibrobiologics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Brian Krause Cascade Financial Partners, LLC | 16,428 | $21,685 | $11,499.6 | -$10,185.4 | -46.97% |
Fibrobiologics Inc. (FBLG) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Fibrobiologics Inc. ever had a stock split?
Fibrobiologics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Peter O'Heeron CEO | NASDAQ (CM) Exchange | 31573L204 CUSIP |
| US Country | 15 Employees | - Last Dividend | 30 Mar 2026 Last Split | - IPO Date |
Overview
FibroBiologics, Inc. is a clinical-stage cell therapy company focused on the development and commercialization of fibroblast-based therapies. The company is at the forefront of exploring and harnessing the potential of fibroblasts in regenerative medicine. Its work spans a range of serious health conditions, including degenerative diseases, autoimmune disorders, and certain types of cancers. Founded in 2021, FibroBiologics has quickly established itself within the biotech industry and is headquartered in Houston, Texas, a hub for medical research and innovation in the United States.
Products and Services
- CybroCell
- CYMS101
- CYWC628
- CYTER915
- CYPS317
- TCB190
Developed for the treatment of degenerative disc disease, CybroCell represents a pioneering approach to address chronic back pain and spinal issues through cell therapy. By utilizing fibroblasts, this treatment aims to repair and regenerate damaged discs, offering a potential alternative to conventional surgeries or long-term medication.
CYMS101 is a cell therapy product in development for treating multiple sclerosis (MS), a chronic autoimmune disease that affects the central nervous system. This innovative treatment is designed to modulate the immune response and repair the myelin sheath around nerve fibers, potentially slowing or halting the progression of MS.
This product targets the acceleration of wound healing processes. CYWC628 could significantly benefit individuals with chronic wounds, such as diabetic ulcers, by promoting faster tissue regeneration and reducing the risk of infections, thereby improving patient outcomes and quality of life.
At the early stages of research, CYTER915 is focused on rejuvenating the thymus and/or spleen to potentially improve immune functions. This therapy could be crucial for aging populations or for those with compromised immune systems, offering a novel way to enhance overall health and resistance to diseases.
For individuals suffering from psoriasis, CYPS317 stands as a promising cell therapy aimed at treating this chronic autoimmune skin condition. By targeting the underlying causes of psoriasis, this therapy could provide lasting relief from symptoms and significantly improve skin health.
TCB190 is a cell therapy product being developed to treat certain types of cancers. By leveraging the natural capabilities of fibroblasts, this treatment aims to target and destroy cancer cells, offering a potentially effective and less invasive alternative to traditional cancer treatments.
